NCT04899908: An ongoing trial by Dana-Farber Cancer Institute
This trial is ongoing. It must report results 2 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04899908 |
|---|---|
| Title | A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 15, 2021 |
| Completion date | Feb. 28, 2025 |
| Required reporting date | Feb. 28, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |